Pulmonx (LUNG) Financials: History & Chart

Pulmonx Corporation(LUNG)

Medical - Devices · Redwood City, CA

$1.78-0.10 (-5.32%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Pulmonx Corporation

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Redwood City, CA

296 employees

pulmonx.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Glendon E. French

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	87.44M	22.76M	20.59M	22.60M	21.50M	23.86M	22.54M	23.77M	20.39M
Cost of Goods Sold	20.06M	5.01M	4.54M	5.06M	5.45M	6.66M	6.20M	6.17M	5.36M
Gross Profit	67.38M	17.74M	16.04M	17.54M	16.05M	17.20M	16.34M	17.59M	15.03M
Gross Profit Margin	77.1%	78.0%	77.9%	77.6%	74.7%	72.1%	72.5%	74.0%	73.7%
Total Operating Expenses	113.69M	26.80M	29.00M	27.44M	30.45M	32.01M	30.91M	31.01M	29.16M
Research & Development	19.36M	5.03M	4.90M	4.58M	4.85M	5.31M	4.76M	4.00M	3.74M
Selling, General & Administrative	94.33M	21.77M	24.10M	22.86M	25.60M	26.70M	26.15M	27.01M	25.41M
Operating Income (EBIT)	-46.31M	-9.06M	-12.96M	-9.90M	-14.39M	-14.80M	-14.56M	-13.42M	-14.13M
Operating Margin	-53.0%	-39.8%	-62.9%	-43.8%	-66.9%	-62.0%	-64.6%	-56.5%	-69.3%
Income Before Tax (EBT)	-47.52M	-9.95M	-13.51M	-10.24M	-13.83M	-15.00M	-14.31M	-13.14M	-13.95M
Interest Income	1.74M	329K	350K	453K	611K	723K	864K	1.04M	1.27M
Interest Expense	3.77M	1.22M	976K	770K	805K	799K	781K	842K	891K
Other Income/Expense	-1.21M	-890K	-549K	-336K	564K	-192K	250K	280K	177K
Net Income	-48.12M	-10.08M	-13.65M	-10.43M	-13.96M	-15.17M	-14.45M	-13.18M	-14.14M
Income Tax Expense	596K	133K	149K	186K	128K	177K	135K	38K	192K
Net Profit Margin	-55.0%	-44.3%	-66.3%	-46.1%	-64.9%	-63.6%	-64.1%	-55.4%	-69.4%
EBITDA	-45.39M	-8.84M	-12.74M	-9.67M	-14.15M	-14.51M	-14.03M	-13.12M	-13.75M
EBITDA Margin	-51.9%	-38.8%	-61.9%	-42.8%	-65.8%	-60.8%	-62.3%	-55.2%	-67.5%
Depreciation & Amortization	919K	222K	220K	231K	246K	299K	531K	294K	376K
EPS Basic	-1.15	-0.23	-0.33	-0.25	-0.34	-0.38	-0.36	-0.33	-0.36
EPS Diluted	-1.15	-0.23	-0.33	-0.25	-0.34	-0.38	-0.36	-0.33	-0.36
Weighted Average Basic Shares	42.18M	42.18M	41.90M	41.40M	40.94M	40.19M	39.95M	39.11M	39.28M
Weighted Average Diluted Shares	42.18M	42.18M	41.90M	41.40M	40.94M	40.19M	39.95M	39.11M	39.28M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	90.50M	83.79M	68.67M	53.66M	48.42M	32.73M	32.59M	20.00M
Cost of Goods Sold	23.36M	21.79M	17.92M	13.80M	12.79M	11.53M	10.18M	7.72M
Gross Profit	67.14M	62.00M	50.75M	39.87M	35.63M	21.20M	22.41M	12.29M
Gross Profit Margin	74.2%	74.0%	73.9%	74.3%	73.6%	64.8%	68.8%	61.4%
Total Operating Expenses	120.80M	119.70M	112.69M	98.50M	82.93M	53.53M	40.25M	27.34M
Research & Development	19.49M	17.57M	18.08M	15.40M	13.06M	7.46M	6.05M	6.99M
Selling, General & Administrative	101.31M	102.14M	94.61M	83.11M	69.87M	46.07M	34.20M	20.35M
Operating Income (EBIT)	-53.66M	-57.70M	-61.94M	-58.64M	-47.30M	-32.33M	-17.84M	-15.05M
Operating Margin	-59.3%	-68.9%	-90.2%	-109.3%	-97.7%	-98.8%	-54.7%	-75.2%
Income Before Tax (EBT)	-53.38M	-55.89M	-60.27M	-58.57M	-48.32M	-32.02M	-20.34M	-18.47M
Interest Income	2.65M	5.06M	5.57M	1.53M	400K	213K	432K	21K
Interest Expense	3.15M	3.51M	3.23M	1.07M	829K	3.18M	2.32M	2.52M
Other Income/Expense	286K	1.81M	1.66M	67K	-1.01M	314K	-2.50M	-3.42M
Net Income	-54.00M	-56.39M	-60.84M	-58.92M	-48.66M	-32.23M	-20.70M	-18.48M
Income Tax Expense	626K	500K	571K	353K	343K	213K	363K	12K
Net Profit Margin	-59.7%	-67.3%	-88.6%	-109.8%	-100.5%	-98.5%	-63.5%	-92.4%
EBITDA	-52.61M	-56.11M	-59.99M	-57.12M	-46.44M	-31.93M	-16.64M	-14.78M
EBITDA Margin	-58.1%	-67.0%	-87.3%	-106.5%	-95.9%	-97.6%	-51.0%	-73.9%
Depreciation & Amortization	1.05M	1.59M	1.95M	1.51M	867K	400K	1.20M	270K
EPS Basic	-1.33	-1.44	-1.60	-1.59	-1.35	-0.90	-0.58	-0.89
EPS Diluted	-1.33	-1.44	-1.60	-1.59	-1.35	-0.90	-0.58	-0.89
Weighted Average Basic Shares	40.69M	39.11M	37.97M	37.10M	36.13M	35.69M	35.43M	20.71M
Weighted Average Diluted Shares	40.69M	39.11M	37.97M	37.10M	36.13M	35.69M	35.43M	20.71M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.